

Supporting Information


Application of aziridinium ring opening for preparation of optically active diamine and triamine analogues:
Highly efficient synthesis and evaluation of DTPA-based MRI contrast enhancement agents:

Xiang Sun,¹ Yunwei Chen,¹ Ningjie Wu,¹ Chi Soo Kang,¹ Hyun A Song,¹ Shengnan Jin,¹
Yao Fu,¹ Henry Bryant Jr.,² Joseph A. Frank,² Hyun-Soon Chong^{1,*}



Table of Contents


I. NMR spectra of compounds -----	p. 2-24
II. Chiral HPLC chromatograms of compounds -----	p. 25-26
III. Relaxivity and ICP-MS data -----	p. 27-28

^1H and ^{13}C NMR Spectra of Compounds








(R)-3a














(R)-3b







































(S)-6















(rac)-6






















15











(R)-16








(S)-16








(rac)-Bn-DTPA








(R)-Bn-DTPA








(S)-Bn-DTPA








18





19






(S)-16



(prepared from the procedure shown in Scheme 5)






(*S*)-Bn-DTPA


(prepared from the procedure shown in Scheme 5)




Chiral HPLC Chromatograms of Compounds




(S)-5 (>99.9%ee)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.375	BB	0.3229	1.43263e4	635.74078	100.0000





(rac)-5




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.124	VB	0.2914	8827.23340	413.00711	46.2904
2	9.624	BB	0.3580	1.02420e4	387.95532	53.7096



(S)-6 (>99.9%ee)




(rac)-6



III. T1 relaxivity of Gd(Bn-DTPA) complexes and ICP-MS measurement


Gd(III)-(S)-Bn-DTPA

conc (mM)	T1 (sec)	1/T1	delay time (sec)
0.404	0.527	1.898	3
0.199	0.928	1.078	5
0.098	1.490	0.671	10
0.050	2.160	0.463	15
0.026	2.750	0.364	15



Gd(III)-(R)-Bn-DTPA

conc (mM)	T1 (sec)	1/T1	delay time (sec)
0.441	0.491	2.037	3
0.212	0.869	1.151	5
0.107	1.423	0.703	10
0.055	2.080	0.481	15
0.027	2.750	0.364	15



Gd(III)-(rac)-Bn-DTPA

conc. (mM)	T1 (sec)	1/T1	delay time (sec)
0.430	0.513	1.949	3
0.212	0.901	1.110	5
0.105	1.459	0.686	10
0.052	2.130	0.469	15
0.026	2.765	0.362	15

